NMN + Resveratrol Stack: Evidence, Dose, Caveats

NMN plus resveratrol is often called the "Sinclair stack": NMN supplies the raw material for NAD+, and resveratrol is meant to switch on the sirtuin enzymes that use it. It is a neat idea, but no human trial has tested the combination. The two halves also have very different evidence: NMN reliably raises blood NAD+, while resveratrol's human results are inconsistent. This page explains what is known, what is not, and how to try the stack sensibly if you choose to.

Evidence grade: D for the combination (no human trials). Grade C for NMN raising blood NAD+ (several small RCTs). Grade C/D for resveratrol's metabolic effects (mixed RCTs).

Key takeaways

• NMN at 300–900 mg/day raised blood NAD+ in a 60-day RCT of 80 middle-aged adults (Yi 2023). At 250 mg/day it improved muscle insulin sensitivity in 25 prediabetic women (Yoshino 2021). Long-term health outcomes are unknown.
• Resveratrol: 150 mg/day improved some metabolic markers in 11 obese men over 30 days (Timmers 2011), while 1,500 mg/day did nothing in 24 obese men (Poulsen 2013).
• Whether resveratrol directly activates SIRT1 has been disputed since 2010, and the answer depends on the lab conditions.
• If you try it, add one ingredient at a time so you can tell what, if anything, is helping.

As an Amazon Associate, Stacking Years earns from qualifying purchases.

The idea behind the stack

Sirtuins (SIRT1–7) are enzymes that consume NAD+ as they work. NAD+ levels fall with age, so the theory is that NMN refills the fuel while resveratrol presses the accelerator. The mechanism comes mainly from cell and animal work. In humans, neither "more NAD+" nor "more sirtuin activity" has yet been shown to slow ageing.

NMN: what human trials show

• Yi et al. 2023 (*GeroScience*; 80 healthy middle-aged adults; 300, 600 or 900 mg/day for 60 days): blood NAD+ rose in every NMN group, most at 600–900 mg. Six-minute walk distance improved more than with placebo, and no safety problems were reported (PMID 36482258). The trial was industry-funded and short.
• Yoshino et al. 2021 (*Science*; 25 overweight or obese postmenopausal women with prediabetes; 250 mg/day for 10 weeks): muscle insulin sensitivity improved, but body composition and blood pressure did not change (PMID 33888596).

Resveratrol: why the evidence is mixed

• Timmers et al. 2011 (*Cell Metab*; 11 obese men; 150 mg/day for 30 days, crossover) reported lower resting metabolic rate, liver fat, glucose and triglycerides (PMID 22055504).
• Poulsen et al. 2013 (*Diabetes*; 24 obese men; high-dose resveratrol for 4 weeks) found no effect on insulin sensitivity, blood pressure, energy expenditure, fat stores or inflammatory markers. The authors questioned resveratrol's use as a supplement (PMID 23193181).
• The SIRT1 debate: Pacholec et al. 2010 reported that resveratrol is not a direct SIRT1 activator (PMID 20061378). Hubbard et al. 2013 then proposed an allosteric mechanism that depends on the substrate (PMID 23471411). Either way, test-tube activation does not guarantee an effect in people.

If you want to try it

Use caution or ask your doctor if you take blood thinners or antiplatelet drugs (resveratrol may add bleeding risk), are pregnant or breastfeeding, or have a hormone-sensitive condition.

Product notes

For NMN, choose a product that names its raw material and has third-party purity testing, such as Toniiq NMN (Uthever). For resveratrol, look for trans-resveratrol with the dose per capsule stated clearly. No product here is ranked or star-rated. For the wider NAD+ picture, including NR and NMN dosing, see the NMN and NAD+ guide.